No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To describe the changes in serum levels of calcitonin in liraglutide- and placebo-treated patients in the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results—A Long Term Evaluation (LEADER) trial over a 3.5–5-year period. RESEARCH DESIGN AND METHODS: Patients (n = 9,340) with type 2 diabetes and high risk for cardiovascular events were randomized 1:1 to liraglutide or placebo. We analyzed calcitonin levels, thyroid and C-cell adverse events, and neoplasms. RESULTS: At 36 months, patients randomized to liraglutide versus placebo showed no evidence of increase in calcitonin concentrations in male (estimated treatment ratio [ETR] 1.03 [95% CI 1.00, 1.06]; P = 0.068) and female (ETR 1.00 [95% CI 0.97, 1.02]; P = 0.671) subgroups. There were no episodes of C-cell hyperplasia or medullary thyroid carcinoma in liraglutide-treated patients. CONCLUSIONS: There was no evidence of a difference in calcitonin concentrations between the liraglutide and placebo groups, and no C-cell malignancies occurred in the liraglutide group.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modest survival benefits also have been reported for breast, ovarian, endometrial, prostate, lung, kidney, liver, and earlier stage pancreatic cancers.1791–1800”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1793]
In the citing paper
“In the LEADER trial, at 36 months, there was no difference in the levels of calcitonin between participants in the placebo or liraglutide arm and no diagnoses of C-cell hyperplasia or MTC in those who received liraglutide and there was one event of MTC in the placebo arm.57”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [57]
In the citing paper
“there was no difference between liraglutide and placebo regarding calcitonin levels and C-cell malignancies”
From Safety of Semaglutide (2021) · cites this paper as [83]
In the citing paper
“A phase 3b RCT showed no difference in the calcitonin levels and rate of medullary thyroid carcinoma between the placebo- and liraglutide-treated (≤ 1.8 mg) groups, during a follow-up after 3.5 years [55].”
From Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? (2021) · cites this paper as [55]
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672
Marso, S. P., Poulter, N. R., Nissen, S. E., Nauck, M. A., Zinman, B., Daniels, G. H., Pocock, S., Steinberg, W. M., Bergenstal, R. M., Mann, J. F. E., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.07.012 · Cited by 245
Self-citationHegedüs, L., Moses, A. C., Zdravkovic, M., Le Thi, T., & Daniels, G. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2318 · Cited by 194 · cited 3×
“In contrast, a different study showed that the calcitonin concentrations were statistically higher at weeks 26 and 52 with liraglutide compared with comparators; however, these levels were well within the normal range and, as with our analysis, showed no indication that these differences were of clinical significance…”
BackgroundResultInfluentialSelf-citationMadsen, L. W., Knauf, J. A., Gotfredsen, C., Pilling, A., Sjögren, I., Andersen, S., Andersen, L., Sietske de Boer, A., Manova, K., Barlas, A., et al. (2012) · Endocrinology · doi:10.1210/en.2011-1864 · Cited by 161
Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls
Costante, G., Durante, C., Francis, Z., Schlumberger, M. J., & Filetti, S. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet1023 · Cited by 143 · cited 5×
“In rodent studies, but not in nonhuman primate and clinical studies, glucagon-like peptide 1 receptor activation has been associated with CCH, C-cell adenomas, and C-cell carcinomas (6–8).”
BackgroundMethodInfluentialRoutine serum calcitonin measurement in the evaluation of thyroid nodules
Elisei, R. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.09.008 · Cited by 98 · cited 1×
“The role of routine calcitonin monitoring for detection of MTC remains ill-defined but may be a more sensitivemethod in establishingMTC than cytology in patients with thyroid nodules (5).”
BackgroundMachens, A., Hoffmann, F., Sekulla, C., & Dralle, H. (2009) · Endocrine-Related Cancer · doi:10.1677/erc-09-0136 · Cited by 83 · cited 1×
“The progression of CCH to MTC is accompanied by rising calcitonin concentrations (2,3).”
BackgroundMedical management of metastatic medullary thyroid cancer
Maxwell, J. E., Sherman, S. K., O’Dorisio, T. M., & Howe, J. R. (2014) · Cancer · doi:10.1002/cncr.28858 · Cited by 49
Self-citationDaniels, G. H., Hegedüs, L., Marso, S. P., Nauck, M. A., Zinman, B., Bergenstal, R. M., Mann, J. F. E., Derving Karsbøl, J., Moses, A. C., Buse, J. B., et al. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12444 · Cited by 42
Self-citation
Cited by
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Thyroid dysfunction and diabetes mellitus: two closely associated disorders
Biondi, B., Kahaly, G. J., & Robertson, R. P. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00163 · Cited by 598
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak, Y. J., & Lee, S. Y. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00422-w · Cited by 343
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
Bezin, J., Gouverneur, A., Pénichon, M., Mathieu, C., Garrel, R., Hillaire-Buys, D., Pariente, A., & Faillie, J.-L. (2023) · Diabetes Care · doi:10.2337/dc22-1148 · Cited by 320
Smits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332
Pharmacotherapy of obesity: available medications and drugs under investigation.
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248
Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review
Tak, Y. J., & Lee, S. Y. (2021) · The World Journal of Men's Health · doi:10.5534/wjmh.200010 · Cited by 184
Links between Thyroid Disorders and Glucose Homeostasis
Eom, Y. S., Wilson, J. R., & Bernet, V. J. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0013 · Cited by 162
“Similarly, in the Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER) Trial, liraglutide did not increase calcitonin or cause C-cell malignancies [127].”
Hu, W., Song, R., Cheng, R., Liu, C., Guo, R., Tang, W., Zhang, J., Zhao, Q., Li, X., & Liu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.927859 · Cited by 127
“5-5 years showed no effect of GLP-1 receptor activation on human serum calcitonin levels, C-cell proliferation or C-cell malignancy (15).”
BackgroundBaxter, S. M., Lund, L. C., Andersen, J. H., Brix, T. H., Hegedüs, L., Hsieh, M. H.-C., Su, C. T.-T., Cheng, M. C.-Y., Chang, Z. C.-J., Lai, E. C.-C., et al. (2025) · Thyroid® · doi:10.1089/thy.2024.0387 · Cited by 81
“14,15 19 In light of the con fl icting evidence and owing to increasing trends in GLP1-RA use, 20 we aimed to evaluate if GLP1-RAs used to treat type 2 diabetes are associated with an increased risk of thyroid cancer across six international sites, with a speci fi c focus on cumulative dose.”
Self-citationThe Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications
Drucker, D. J. (2018) · Diabetes · doi:10.2337/dbi18-0008 · Cited by 78
GLP-1RA Use and Thyroid Cancer Risk
Brito, J. P., Herrin, J. S., SWARNA, K. S., Ospina, N. S., Montori, V. M., Toro-Tobón, D., Umpierrez, G. E., Galindo, R. J., Deng, Y., Mickelson, M. M., et al. (2025) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2024.4852 · Cited by 76
Medications for the treatment of obesity in adolescents
Woodard, K., Louque, L., & Hsia, D. S. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820918789 · Cited by 53
Andersen, D. B., Grunddal, K. V., Pedersen, J., Kuhre, R. E., Lund, M. L., Holst, J. J., & Ørskov, C. (2021) · Endocrinology · doi:10.1210/endocr/bqaa246 · Cited by 54
Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes
Petri, K. C. C., Ingwersen, S. H., Flint, A., Zacho, J., & Overgaard, R. V. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13358 · Cited by 53
“No evidence of increased calcitonin concentrations was likewise found with liraglutide compared with placebo after 3 years.(28) Limitations of the present study include that maintenance doses were limited to 0.”
BackgroundMali, G., Ahuja, V., & Dubey, K. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13259 · Cited by 44
“[23] 2018 Randomized, double-blind, controlled trial Liraglutide Placebo 36 months C-cell hyperplasia or MTC - none”
BackgroundBethel, M. A., Patel, R. A., Thompson, V. P., Merrill, P., Reed, S. D., Li, Y., Ahmadi, S., Katona, B. G., Gustavson, S. M., Ohman, P., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2028 · Cited by 43
Patoulias, D., Doumas, M. N., Kotsis, V., Stavropoulos, K., Imprialos, K. P., Zografou, I., Petidis, K., Bakatselos, S., & Karagiannis, A. I. (2020) · Current Diabetes Reviews · doi:10.2174/1573399815666190614141918 · Cited by 53
Anti-Diabetic Therapies and Cancer: From Bench to Bedside
Kounatidis, D. C., Vallianou, N. G., Karampela, Ι., Rebelos, E., Kouveletsou, M., Dalopoulos, V., Koufopoulos, P., Diakoumopoulou, E., Tentolouris, N., & Dalamaga, Μ. (2024) · Biomolecules · doi:10.3390/biom14111479 · Cited by 52
Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
Lisco, G., De Tullio, A., Disoteo, O., Piazzolla, G., Guastamacchia, E., Sabbà, C., De Geronimo, V., Papini, E., & Triggiani, V. (2023) · Endocrine Connections · doi:10.1530/ec-23-0257 · Cited by 37
Capuccio, S., Scilletta, S., Rocca, F. L., Miano, N., Marco, M. D., Bosco, G., Barbagallo, F. D. G., Scicali, R., Piro, S., & Pino, A. D. (2024) · Biomolecules · doi:10.3390/biom14060687 · Cited by 48
Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review
Espinosa De Ycaza, A. E., Brito, J. P., McCoy, R. G., Shao, H., & Singh Ospina, N. (2024) · Thyroid · doi:10.1089/thy.2023.0530 · Cited by 37
“55,57 In the LEADER trial, at 36 months, there was no difference in the levels of calcitonin between participants in the placebo or liraglutide arm and no diagnoses of C-cell hyperplasia or MTC in those who received liraglutide and there was one event of MTC in the placebo arm.”
Barrea, L., Pugliese, G., Muscogiuri, G., Laudisio, D., Colao, A. A. L., & Savastano, S. (2020) · Minerva Endocrinology · doi:10.23736/s0391-1977.20.03179-x · Cited by 38
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Son, J. W., & Lim, S. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1940 · Cited by 33
“In a long-term evaluation of the LEAD-ER trial with 9,340 patients with T2D over a 3.5-to 5-year period, there was no evidence of C-cell malignancies occurred in the liraglutide group [84].”
BackgroundInfluentialReview of Associations Between Type 2 Diabetes and Cancer
Bonagiri, P. R., & Shubrook, J. H. (2020) · Clinical Diabetes · doi:10.2337/cd19-0077 · Cited by 33
Approach to the patient with thyroid nodules: considering GLP-1 receptor agonists
Kelly, C. A., & Sipos, J. A. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae722 · Cited by 30
Grigoriadis, G., Koufakis, T., & Kotsa, K. (2023) · Medicina · doi:10.3390/medicina59112013 · Cited by 37
“However, a sub-analysis of the LEADER trial that evaluated the long-term effects of liraglutide in T2DM patients reported no adverse effects on the thyroid gland [107].”
BackgroundPotential kidney protective effects of glucagon‐like peptide‐1 receptor agonists
Trevella, P., Ekinci, E. I., & MacIsaac, R. J. (2024) · Nephrology · doi:10.1111/nep.14336 · Cited by 26
Pharmacotherapy of Weight‐loss and Obesity with a Focus on GLP 1‐Receptor Agonists
Myerson, M. L., & Paparodis, R. D. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2487 · Cited by 20
“72,73 No increase in serum calcitonin was observed in a patient using dulaglutide (Trulicity) as well, who was diagnosed with medullary thyroid carcinoma prior to the medication introduction.”
Daou, C. A. Z., Hosn, O. A., Ghzayel, L., & Mourad, M. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70038 · Cited by 25
“Clinical findings vary, with some studies reporting no significant changes in serum calcitonin or thyroid malignancies after long-term liraglutide use [17].”
Kupnicka, P., Król, M., Żychowska, J., Łagowski, R., Prajwos, E., Surówka, A., & Chlubek, D. (2024) · Pharmaceuticals · doi:10.3390/ph17111470 · Cited by 26
Novel Treatments for Obesity: Implications for Cancer Prevention and Treatment
Cuttica, C. M., Briata, I. M., & DeCensi, A. (2023) · Nutrients · doi:10.3390/nu15173737 · Cited by 18
“However, although there is no clear evidence of the development of c-cell malignancies, it should be noted that GLP-1RAs are currently not recommended in patients with family or personal history of medullary thyroid cancer, as well as multiple endocrine neoplasia syndrome type 2 [74,75].”
Safety of injectable semaglutide for type 2 diabetes
Peter, R., & Bain, S. C. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1772230 · Cited by 17
Khunti, K., Almalki, M., Chan, J. C. N., & Amod, A. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01458-6 · Cited by 19
Impaired Glucose Metabolism, Anti-Diabetes Medications, and Risk of Thyroid Cancer
Kushchayeva, Y. S., Kushchayev, S. V., Jensen, K. E., & Brown, R. J. (2022) · Cancers · doi:10.3390/cancers14030555 · Cited by 20
Glucagon-like peptide-1 medicines and cancer
Yabut, J. M., & Drucker, D. J. (2026) · Nature Cancer · doi:10.1038/s43018-025-01110-1 · Cited by 15
“By contrast, GLP-1R expression is very low or undetectable in normal thyroid C cells from monkeys and humans, and GLP-1 medicines do not stimulate calcitonin secretion or C cell proliferation in humans 19,55 .”
Wu, H., Lu, Z., Chen, R., Cai, Q., Wang, M., Zhang, L., & Zhu, Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1098032 · Cited by 15
“However, the LEADER trial (28) in T2DM patients and a meta-analysis (29) excluded a major increase in the risk of total malignant neoplasms (including pancreatic and thyroid neoplasms) with liraglutide treatment.”
BackgroundLiraglutide Therapy in a Prediabetic State: Rethinking the Evidence
Papaetis, G. S. (2019) · Current Diabetes Reviews · doi:10.2174/1573399816666191230113446 · Cited by 11
Glucagon-like peptide-1 receptor agonists in neoplastic diseases
Ji, L., He, X., Min, X., Yang, H., Wu, W., Xu, H., Chen, J., & Mei, A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1465881 · Cited by 12
“Studies of the same species also varied, with a follow-up of patients treated with GLP-1RAs (74) showing no signi fi cant difference in calcitonin concentrations between liraglutide and placebo and no change in the risk of thyroid C-cell tumors.”
Zhang, Z., Yang, J., & Gao, L. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.013 · Cited by 9
Lee, C. J., Kim, M.-J., & An, S. J. (2019) · Daehan imsang geon-gang jeungjin hakoeji/Daehan imsang geon'gang jeungjin haghoeji · doi:10.15384/kjhp.2019.19.4.171 · Cited by 5
Effect of GLP-1 Receptor Agonists on Patients with Thyroid Carcinomas Undergoing Active Surveillance
Patrizio, A., Newman, S. K., Tuttle, R. M., & Boucai, L. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf182 · Cited by 7
“However, these effects have not been observed in primates or humans, and clinical data to date have not shown a notable rise in MTC cases among GLP-1RA users [7, 8].”
Self-citationExposure to GLP-1RA and Risk of Structural Progression in Differentiated Thyroid Cancer
Patrizio, A., Mauguen, A., Fagin, J. A., Farooki, A., Fish, S. A., Flory, J., Newman, S. K., Presswala, L. S., Sabra, M. M., Tuttle, R. M., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag051 · Cited by 5
Self-citationWeight-centric prevention of cancer
Añazco, D., Acosta, A. J., Cathcart-Rake, E. J., D’Andre, S. D., & Hurtado, M. D. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100106 · Cited by 5
“In addition, a study that randomized 9340 patients with type 2 diabetes to either liraglutide or placebo reported that liraglutide did not significantly increase calcitonin levels at 36 months, with no episodes of C-cell hyperplasia or MTC in patients treated with liraglutide [84].”
BackgroundCurrent pharmacological approaches in obesity treatment
TİRYAKİOĞLU, P., Yilmaz, H., Demir, İ., & Yilmaz, I. C. (2023) · DAHUDER Medical Journal · doi:10.56016/dahudermj.1271677 · Cited by 5
Lingow, S. E., Carris, N. W., Clements, J. N., Courtney, L. A., Lennon, A., Sherrill, C. H., & Dril, E. V. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70111 · Cited by 5
“However, results from the LEADER trial showed no C-cell malignancies after 3.5–5 years of follow-up in those treated with liraglutide, and another meta-analysis concluded that GLP-1 RAs did not increase the risk of thyroid cancer or other thyroid disorders [57, 58].”
InfluentialWatts, E., Wadsley, J., Sharma, N., Boelaert, K., & The UK Thyroid Cancer Study Group (2025) · Clinical Endocrinology · doi:10.1111/cen.70084 · Cited by 7
Hypercalcemia Induced by Tirzepatide and Calcium Supplementation: A Case Report
Nguyen, E., Kawamura, M., Munoz, I., & Ahn, G. (2026) · Cureus · doi:10.7759/cureus.108061 · Cited by 2
“There is a paucity of literature looking at the impacts of tirzepatide or other GLP-1R agonists on PTH, vitamin D levels, or CaSR activity [9].”
Challenges in Thyroid Function Testing: Interferences and Clinical Implications
de Carvalho, G. A., & Drobrzenski, B. (2023) · Medical Research Archives · doi:10.18103/mra.v11i8.4340 · Cited by 2
Glucagon-like Peptide 1 Receptor Agonists Do Not Alter Calcitonin Levels in Humans
Toft, D. J. (2019) · Clinical Thyroidology · doi:10.1089/ct.2019;31.253-255 · Cited by 1
“The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) included 9340 patients treated with liraglutide (1.8 mg daily) or placebo; it also found no difference in calcitonin levels between treated groups over the 3-year follow-up period (5).”
InfluentialSemaglutide and weight management in the Arab countries: Focus on the United Arab Emirates
Semiz, S. (2025) · Health Sciences Review · doi:10.1016/j.hsr.2025.100244 · Cited by 2
Metabolic syndrome and cancer risk
Majumder, A., & Acharya, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00052-9 · Cited by 1
GLP-1-Analoga: Was ist in der Praxis zu beachten?
Ritzel, R. A. (2020) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-020-0390-2
Onkodiabetológia II. Antidiabetikumok és rákmegelőzés
Bánhegyi, R. J., Gazdag, A., Rácz, B., Szalai, L., Wagner, R. J., & Fülöp, N. (2022) · Orvosi Hetilap · doi:10.1556/650.2022.32041 · Cited by 2
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
Παππά, Θ. (2023) · Clinical Thyroidology · doi:10.1089/ct.2023;35.18-20
Topaloğlu, Ö., & Toksöz, D. Y. (2023) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-023-01197-1
“The effect of exenatide on the occurrence of thyroid cancer is controversial [10–14].”
János, B. R. (2023) · Pesci Egyetemi Archivum (University of Pécs) · doi:10.15170/pte.2023.004
Glucagon-like Peptide-1 Receptor Agonists and Thyroid Cancer: Myth or Reality?
Goldenberg, R. (2025) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2025.3137
Khawandanah, D. O., Alyamani, F. F., Almutairi, B. R., Almutairi, B. A., Alharbi, R. M., Alghanmi, S., Alsouri, M. T., & ALMUTAIRI, A. R. (2025) · Saudi Journal of Clinical Pharmacy · doi:10.4103/sjcp.sjcp_22_25 · Cited by 1
Inkretinmimetika und Schilddrüsenkrebs: Gibt es ein Risiko?
Parzer, V. (2026) · Journal für Endokrinologie Diabetologie und Stoffwechsel · doi:10.1007/s41969-026-00297-7
Salama, S., Omer, E. O. E., Mahmoud, A., ElshikhIdris, M. A. M., Hussien, T. M. M., Ahmed, M., Fadulelsayed, S. O., Ibrahim, S. A. M., Mohammed, H. O. A., & Alhajri, A. H. M. (2026) · Cureus · doi:10.7759/cureus.108005 · Cited by 2
“Conversely, the LEADER trial analysis by Hegedüs et al. [20] found no clinically meaningful differences in thyroid hormones over 3.8 years.”
InfluentialPorter, M. W., Ghorbani, T., & Cubb, T. D. (2026) · Clinical Thyroidology · doi:10.1177/23299711261441003
Zhong, Q., Yang, A. L., & Volic, I. N. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.00999-4
GLP-1 RECEPTOR AGONISTS AND THYROID DISEASE: FROM MECHANISM TO CLINICAL PRACTICE
Milewska, A., Bociąg, A., Kowalski, K., Marciniak, R., & Ptach, Ł. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(52).2026.6324
Al-Mashhadani, M. M., Khalifa, A., Al-Mashhadani, Y., Ajaz, F., Barragán, C., & Alsaeed, M. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113630
Metadata
- Authors
- Hegedüs, L., Sherman, S. I., Tuttle, R. M., von Scholten, B. J., Rasmussen, S., Karsbøl, J. D., Daniels, G. H., & for the LEADER Publication Committee on behalf of the LEADER Trial Investigators
- Affiliations
- Department of Endocrinology, Odense University Hospital, Odense, Denmark
- The University of Texas MD Anderson Cancer Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- Novo Nordisk A/S, Søborg, Denmark
- Novo Nordisk (Denmark) (DK)
- Harvard University (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-12-26
- Volume
- 41
- Issue
- 3
- Pages
- 620-622
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2778933123
- Cited by
- 67
- References
- 10
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 12 · 2023: 10 · 2022: 6 · 2021: 2 · 2020: 9 · 2019: 6 · 2018: 3
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- liraglutide, calcitonin, C-cell hyperplasia, medullary thyroid carcinoma, type 2 diabetes, GLP-1 receptor agonists, thyroid cancer risk, long-term safety, cardiovascular outcomes, LEADER trial
- MeSH terms
- Liraglutide, Calcitonin, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Follow-Up Studies, Humans, Hyperplasia, Hypoglycemic Agents, Male, Middle Aged, Neoplasms, Thyroid Neoplasms, Biomarkers, Tumor, Body Mass Index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.